Pharmaniaga

Pharmaniaga Berhad
TypePublic limited company
Traded as
MYX: 7081
Industry
PredecessorSouthern Task (M) Sdn Bhd (1994)
Remedi Pharmaceuticals (1994-1998)[1]
Founded1994 (1994)
FounderUEM Group
HeadquartersShah Alam, Selangor, Malaysia
Area served
Worldwide
Key people
Izaddeen Daud, Chairman; interim Executive Committee (EXCO) comprising Ahmad Shahredzuan Mohd Shariff, Non-Independent Non-Executive Director; Zulkifli Jafar, Deputy Chief Executive Officer; Mohamed Iqbal Abdul Rahman, Chief Operating Officer and Norai'ni Mohamed Ali, Chief Financial Officer
ProductsPrescription drugs, over-the-counter drugs, biopharmaceuticals
RevenueRM4,815,015,000 (FY 2021)
Net income
RM172,205,000 (FY 2021)
Number of employees
Over 3,600
ParentBoustead Holdings
Subsidiaries
  • Pharmaniaga Logistics Sdn Bhd
  • Pharmaniaga Marketing Sdn Bhd
  • Pharmaniaga Research Centre Sdn Bhd
  • Pristine Pharma Sdn Bhd
  • Paradigm Industry Sdn Bhd
  • Pharmaniaga Manufacturing Bhd
  • Idaman Pharma Manufacturing Sdn Bhd (Sungai Petani)
  • Idaman Pharma Manufacturing Sdn Bhd (Seri Iskandar)
  • Pharmaniaga LifeScience Sdn Bhd
  • PT Millennium Pharmacon International TBK
  • PT Errita Pharma
Websitewww.pharmaniaga.com

Pharmaniaga Berhad (Pharmaniaga) is a Malaysian pharmaceutical company. It is a subsidiary of Boustead Holdings, an affiliate of the Malaysian military.

History

Pharmaniaga was established in 1994 as Remedi Pharmaceuticals.[1] The company was renamed as Pharmaniaga in August 1998 and is the first healthcare company in Malaysia to be listed in the Main Market of Kuala Lumpur Stock Exchange (now Bursa Malaysia).[2]

Ownership

Pharmaniaga is a public limited company. Its two major shareholders are Boustead Holdings and Lembaga Tabung Angkatan Tentera (LTAT). The major owner of Boustead Holdings is itself LTAT.

The Company's Board Members comprise Izaddeen Daud, Non-Independent Non-Executive Chairman; Dr Abdul Razak Ahmad, Senior Independent Non-Executive Director; Sarah Azreen Abdul Samat, Independent Non-Executive Directors; Ahmad Shahredzuan Mohd Shariff, Non-Independent Non-Executive Director; Mohammad Ashraf Md. Radzi, Non-Independent Non-Executive Director and Dayana Rogayah Omar, Non-Independent Non-Executive Director (Alternate to Mohammad Ashraf Md. Radzi).

On 14 March, Pharmaniaga has formed an executive committee (EXCO) in the interim, comprising Ahmad Shahredzuan Mohd Shariff, Non-independent Non-Executive Director; Zulkifli Jafar, Deputy Chief Executive Officer; Mohamed Iqbal Abdul Rahman, Chief Operating Officer and Norai'ni Mohamed Ali, Chief Financial Officer.

Business Overview

Pharmaniaga is involved in various segments of the pharmaceutical value chain, including research and development, manufacturing of generic drugs and medical devices, logistics and distribution, sales and marketing, as well as community pharmacy.

Pharmaniaga has over 3,600 employees, and more than 300 scientists, including researchers, chemists, pharmacologists, formulators, IT engineers, regulatory and clinical affairs specialists.

With eight manufacturing plants, Pharmaniaga is capable of producing products in various forms; from oral solids, liquids and creams to small volume injectables.  Its product portfolio encompasses a diverse segment of therapeutic areas such as cardiovascular, anti-diabetic, antibiotics, antivirals, over the counter products and nutraceuticals, amongst others.

Its Indonesia operations include two manufacturing plants and a public listed pharmaceutical logistics and distribution company with 33 branches throughout the republic.

References

  1. 1 2 Malaysia’s Top 10 pharmaceutical companies Top10malaysia (August 26, 2015). Retrieved on August 26, 2015.
  2. ↑ Pharmaniaga Berhad: An analysis UK Essay (April 5, 2017). Retrieved on April 5, 2017.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.